ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Tim-3 expression is increased on peripheral T cells from diffuse large B cell lymphoma.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma.Cells · 2026Review
- Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment.Frontiers in pharmacology · 2023Review
- Single-Cell RNA-Seq and Bulk RNA-Seq Reveal Intratumoral Heterogeneity and Tumor Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.Frontiers in genetics · 2022Article
- Immune-Checkpoint Inhibitors in B-Cell Lymphoma.Cancers · 2021Review
- Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL).Disease markers · 2021Review
- Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma.Cancers · 2020Review
- Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3Journal of immunology research · 2020Article
- The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma.Oncotarget · 2019Article
- Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy.Cancer immunology, immunotherapy : CII · 2017Article
- Abnormal expression of Tim-3 antigen on peripheral blood T cells is associated with progressive disease in osteosarcoma patients.FEBS open bio · 2016Article
- Microenvironment abnormalities and lymphomagenesis: Immunological aspects.Seminars in cancer biology · 2015Review
- Roles of PD-1, Tim-3 and CTLA-4 in immunoregulation in regulatory T cells among patients with sepsis.International journal of clinical and experimental medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T cell immunoglobulin- and mucin-domain-containing molecule 3 (Tim-3) plays a critical role in immune tolerance by suppressing the activation and proliferation of T cells. The purpose of this study was to investigate the effect of Tim-3 on the development of diffuse large B cell lymphoma (DLBCL). A total of 40 newly diagnosed DLBCL patients and 30 healthy donors were recruited. Tim-3 expression on peripheral CD4+ T and CD8+ T cells was analyzed by flow cytometry. Data showed that expression of Tim-3 was significantly increased on both CD4+ and CD8+ T cells in DLBCL patients than in healthy controls (P < 0.001 and P < 0.001, respectively). Also, level of Tim-3 on CD4+ T cells was positively correlated with CD8+ T cells in patients (P < 0.001). Further analyses revealed that patients with advanced tumor stages had elevated Tim-3 expression on CD4+ and CD8+ T cells compared to those with primary tumor stages. In addition, levels of Tim-3 on CD4+ and CD8+ T cells were significantly elevated in DLBCL patients with bone marrow involvement or B symptoms. Our results suggest that Tim-3 is involved in the development of DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.